
  
    
      
        Background_NNP
        With_IN breakthroughs_NNS in_IN molecular_JJ biology_NN ,_, basic_JJ
        immunology_NN and_CC biotechnology_NN ,_, great_JJ progress_NN has_VBZ been_VBN made_VBN
        in_IN the_DT field_NN of_IN tumor_NN immunology_NN ._. An_DT increasing_VBG number_NN of_IN
        tumor_NN antigens_NNS have_VBP been_VBN identified_VBN [_NN 1_CD ]_NN ._. Tumor_NNP vaccines_NNS
        have_VBP been_VBN successful_JJ in_IN eliciting_VBG tumor-specific_JJ CD_NNP 4_CD
        +_NN and_CC /_NN or_CC CD_NNP 8_CD +_NN T_NN cell_NN responses_NNS ._. However_RB ,_, when_WRB T_NN cells_NNS
        reactive_JJ against_IN tumor_NN antigens_NNS are_VBP expanded_VBN ex_FW vivo_NN and_CC
        then_RB transferred_VBN back_RB into_IN tumor-bearing_JJ hosts_NNS ,_, results_NNS
        have_VBP been_VBN mixed_JJ in_IN treating_VBG both_DT melanoma_NN [_NN 2_CD 3_CD 4_CD ]_NN and_CC
        lymphoma_NN [_NN 5_CD 6_CD 7_CD ]_NN ._. Several_JJ explanations_NNS for_IN these_DT
        variable_JJ results_NNS have_VBP been_VBN suggested_VBN by_IN studies_NNS of_IN T_NN cell_NN
        immunity_NN in_IN mice_NNS ,_, involving_VBG experimental_JJ tumors_NNS derived_VBN
        from_IN inoculation_NN of_IN cell_NN lines_NNS ._. In_IN some_DT circumstances_NNS ,_, CD_NNP 4_CD
        +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD rendered_VBN inactive_JJ in_IN tumor-bearing_JJ
        hosts_NNS [_NN 8_CD ]_NN ._. The_DT inactivation_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS has_VBZ been_VBN
        attributed_VBN either_CC to_TO the_DT tumor_NN cells_NNS themselves_PRP or_CC to_TO bone_NN
        marrow-derived_JJ cells_NNS [_NN 9_CD 10_CD 11_CD ]_NN ,_, whereas_IN antigen_NN
        ignorance_NN or_CC loss_NN of_IN memory_NN have_VBP been_VBN postulated_JJ to_TO
        underlay_NN that_IN of_IN CD_NNP 8_CD +_NN T_NN cells_NNS [_NN 12_CD 13_CD ]_NN ._. Other_JJ studies_NNS
        have_VBP suggested_VBN that_IN tumor_NN cells_NNS can_MD secrete_NN
        immunosuppressive_JJ factors_NNS such_JJ as_IN TGF-β_NNP or_CC express_VB Fas_NNP
        ligand_NN to_TO induce_VB apoptosis_NNS of_IN infiltrating_VBG lymphocytes_NNS [_NN 14_CD
        15_CD 16_CD ]_NN ._. Furthermore_RB ,_, the_DT tumor_NN vasculature_NN appears_VBZ to_TO be_VB
        quite_RB different_JJ from_IN normal_JJ blood_NN vessels_NNS ,_, in_IN terms_NNS of_IN
        structural_JJ organization_NN ,_, interstitial_NN pressure_NN ,_, and_CC flow_NN
        patterns_NNS [_NN 17_CD ]_NN ,_, and_CC in_IN reduced_VBN lymphocyte_NN and_CC natural_JJ
        killer_NN cell_NN homing_VBG and_CC adhesion_NN [_NN 18_CD 19_CD 20_CD 21_CD ]_NN ._. The_DT
        existence_NN of_IN significant_JJ barriers_NNS to_TO effective_JJ
        immunological_JJ destruction_NN is_VBZ further_RBR illustrated_VBN by_IN a_DT mouse_NN
        model_NN of_IN concurrent_JJ multistage_NN tumorigenesis_NNS and_CC
        anti-oncogene_JJ autoimmunity_NN ,_, wherein_WRB progenitor_NN dysplastic_JJ
        lesions_NNS are_VBP infiltrated_VBN and_CC disrupted_VBN ,_, while_IN solid_JJ tumors_NNS
        are_VBP not_RB [_NN 22_CD ]_NN ._. The_DT hypothesis_NNS is_VBZ that_IN the_DT
        microenvironment_NN of_IN certain_JJ types_NNS of_IN solid_JJ tumor_NN can_MD serve_VB
        to_TO locally_RB suppress_VB T_NN cell_NN infiltration_NN ._. In_IN such_JJ cases_NNS ,_, one_CD
        of_IN the_DT challenges_NNS for_IN tumor_NN immunology_NN is_VBZ to_TO find_VB effective_JJ
        means_VBZ to_TO overcome_VB these_DT barriers_NNS to_TO productive_JJ efficacious_JJ
        anti-tumor_JJ immunity_NN ._.
        Herein_NNP we_PRP sought_VBD to_TO modulate_VBP anti-tumor_JJ immunity_NN in_IN a_DT
        transgenic_JJ mouse_NN tumor_NN model_NN in_IN which_WDT an_DT oncogene_NN ,_, SV_NNP 40_CD
        large_JJ T_NN antigen_NN (_( Tag_NNP )_) ,_, is_VBZ expressed_VBN in_IN islet_NN beta_NN cells_NNS
        under_IN the_DT control_NN of_IN the_DT rat_NN insulin_NN promoter_NN ,_, Rip_NNP 1_CD [_NN 23_CD ]_NN
        ._. Several_JJ lines_NNS of_IN Rip_NNP 1_CD -_: Tag_NNP mice_NNS have_VBP been_VBN generated_VBN and_CC
        characterized_VBN ._. Depending_VBG on_IN the_DT temporal_JJ and_CC spatial_NN order_NN
        of_IN Tag_NNP expression_NN ,_, the_DT Rip_NNP 1_CD -_: Tag_NNP mice_NNS are_VBP either_CC
        immunologically_RB tolerant_NN or_CC responsive_JJ to_TO Tag_NNP [_NN 24_CD 25_CD ]_NN ._.
        Mice_NNS in_IN the_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD line_NN begin_VB to_TO express_VB Tag_NNP during_IN
        embryogenesis_NNS ._. The_DT mice_NNS show_VBP systemic_JJ tolerance_NN to_TO Tag_NNP ,_,
        mounting_VBG neither_DT humoral_NN nor_CC cellular_JJ immune_JJ responses_NNS to_TO
        Tag_NNP upon_IN immunization_NN of_IN purified_JJ protein_NN [_NN 25_CD 26_CD ]_NN ._.
        Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS display_VBP a_DT reproducible_JJ pattern_NN of_IN multistage_NN
        tumor_NN development_NN ,_, from_IN normal_JJ islets_NNS to_TO
        hyperplastic_JJ /_NN dysplastic_JJ islets_NNS ,_, to_TO angiogenic_JJ islets_NNS ,_, to_TO
        varying_VBG grades_NNS of_IN solid_JJ tumor_NN ,_, with_IN a_DT well-defined_JJ
        angiogenic_JJ progression_NN [_NN 27_CD ]_NN ._. All_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS succumb_NN
        to_TO hypoglycemia_NN and_CC tumor_NN burden_NN by_IN 13_CD -_: 16_CD weeks_NNS ._. Mice_NNS with_IN
        transgenes_NNS encoding_VBG T_NN cell_NN receptors_NNS from_IN H-_NNP 2_CD k-restricted_JJ
        CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cell_NN clones_NNS specific_JJ for_IN Tag_NNP have_VBP been_VBN
        generated_VBN [_NN 28_CD 29_CD ]_NN ._. When_WRB Rip_NNP 1_CD -_: Tag_NNP 2_CD was_VBD crossed_VBN to_TO TCR_NNP
        transgenic_JJ mice_NNS (_( TCR_NNP 1_LS )_) carrying_VBG Tag-specific_NNP CD_NNP 4_CD +_NN T_NN cells_NNS ,_,
        temporal_JJ induction_NN of_IN T_NN cell_NN tolerance_NN to_TO Tag_NNP was_VBD detected_VBN
        in_IN the_DT pancreatic_JJ draining_NN lymph_NN nodes_NNS in_IN the_DT double_JJ
        transgenic_JJ mice_NNS [_NN 30_CD ]_NN ._. The_DT T_NN cell_NN tolerance_NN is_VBZ manifested_JJ
        in_IN reductions_NNS both_DT of_IN idiotypic_JJ CD_NNP 4_CD +_NN T_NN cell_NN abundance_NN and_CC
        of_IN the_DT T_NN cell_NN proliferation_NN response_NN to_TO Tag_NNP in_IN vitro_NN ._.
        Another_DT line_NN of_IN Rip-_NNP Tag_NNP mice_NNS ,_, Rip_NNP 1_CD -_: Tag_NNP 5_CD has_VBZ a_DT different_JJ
        spatial_NN and_CC temporal_JJ order_NN of_IN Tag_NNP expression_NN [_NN 24_CD ]_NN ._. Tag_NNP
        expression_NN begins_VBZ at_IN approximately_RB 10_CD weeks_NNS of_IN age_NN ._. Several_JJ
        weeks_NNS later_RB ,_, a_DT spontaneous_JJ autoimmune_JJ response_NN to_TO Tag_NNP is_VBZ
        readily_RB detectable_JJ ,_, with_IN significant_JJ lymphocyte_NN
        infiltration_NN of_IN hyperplastic_JJ /_NN dysplastic_JJ islets_NNS ._. Mice_NNS in_IN
        this_DT line_NN readily_RB mount_VB a_DT humoral_NN and_CC CTL_NNP response_NN to_TO Tag_NNP ,_,
        and_CC as_IN such_JJ are_VBP non-tolerant_JJ ._. Infiltration_NNP of_IN premalignant_NN
        lesions_NNS is_VBZ variable_JJ and_CC occasionally_RB intense_JJ ,_, but_CC is_VBZ
        minimal_JJ in_IN solid_JJ tumors_NNS ._. Crosses_NNP of_IN Rip_NNP 1_CD -_: Tag_NNP 5_CD mice_NNS to_TO
        transgenic_JJ mice_NNS that_IN either_DT increased_VBD the_DT abundance_NN of_IN
        anti-_NN Tag_NNP CD_NNP 4_CD +_NN T_NN cells_NNS (_( TCR_NNP 1_LS )_) [_NN 28_CD ]_NN or_CC rendered_VBD the_DT tumor_NN
        cells_NNS co-stimulatory_JJ (_( Rip-_NNP B_NNP 7_CD -_: 1_LS )_) [_NN 31_CD ]_NN dramatically_RB
        enhanced_VBD the_DT infiltration_NN of_IN premalignant_NN lesions_NNS ,_, but_CC not_RB
        of_IN solid_JJ tumors_NNS [_NN 22_CD ]_NN ._. Additionally_RB ,_, ex_FW vivo_NN stimulated_VBN
        Tag-specific_NNP CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD transferred_VBN into_IN Rip_NNP 1_CD -_: Tag_NNP 5_CD ._.
        Like_IN many_JJ of_IN the_DT adoptive_JJ transfers_NNS of_IN tumor-specific_JJ T_NN
        cells_NNS in_IN clinical_JJ cases_NNS [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ,_, no_DT significant_JJ
        lymphocyte_NN infiltration_NN into_IN solid_JJ tumor_NN was_VBD detected_VBN [_NN 22_CD
        ]_NN ._. If_IN ,_, however_RB ,_, Rip_NNP 1_CD -_: Tag_NNP 5_CD mice_NNS were_VBD treated_VBN with_IN lethal_JJ
        radiation_NN and_CC subsequent_JJ reconstitution_NN with_IN bone_NN marrow_NN
        from_IN RAG_NNP 1_CD deficient_NN mice_NNS prior_RB to_TO T_NN cell_NN transfer_NN ,_, modest_JJ
        lymphocyte_NN infiltration_NN into_IN solid_JJ tumors_NNS was_VBD noted_VBN [_NN 22_CD ]_NN
        ;_: however_RB ,_, this_DT study_NN did_VBD not_RB assess_VB the_DT efficacy_NN of_IN that_DT
        response_NN ._. Sub-lethal_NNP irradiation_NN has_VBZ been_VBN successfully_RB used_VBN
        to_TO decrease_VB tumor_NN burden_NN in_IN combination_NN with_IN a_DT
        cytokine-producing_JJ tumor_NN vaccine_NN in_IN a_DT murine_NN renal_JJ cell_NN
        carcinoma_NN lung_NN metastases_NNS model_NN [_NN 32_CD ]_NN ._.
        In_IN the_DT current_JJ study_NN ,_, we_PRP sought_VBD to_TO achieve_VB efficacious_JJ
        anti-tumor_JJ immunity_NN by_IN disrupting_VBG the_DT evident_JJ barriers_NNS
        presented_VBN by_IN solid_JJ tumors_NNS in_IN the_DT Rip-_NNP Tag_NNP model_NN ._. We_PRP chose_VBD
        the_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD line_NN ,_, for_IN its_PRP$ phenotype_NN of_IN rapid_JJ ,_, largely_RB
        synchronous_JJ tumorigenesis_NNS ,_, and_CC its_PRP$ systemic_JJ tolerance_NN ,_,
        reasoning_NN that_IN effects_NNS of_IN experimental_JJ manipulations_NNS could_MD
        be_VB readily_RB distinguished_VBN ._. Lethal_NNP dose_NN radiation_NN followed_VBN by_IN
        bone_NN marrow_NN transplant_NN can_MD significantly_RB impair_VB the_DT
        responsiveness_NNS of_IN anti-tumor_JJ CD_NNP 8_CD +_NN T_NN cells_NNS ,_, dendritic_JJ cells_NNS ,_,
        eosinophiles_NNS and_CC macrophages_NNS [_NN 8_CD ]_NN ,_, and_CC is_VBZ a_DT clinically_RB
        undesirable_JJ therapeutic_JJ modality_NN ._. Therefore_RB ,_, we_PRP
        hypothesized_VBN that_IN sub-lethal_JJ radiation_NN might_MD be_VB more_RBR
        effective_JJ and_CC clinically_RB acceptable_JJ in_IN promoting_VBG anti-tumor_JJ
        immunity_NN ._. The_DT results_NNS presented_VBN in_IN this_DT study_NN suggest_VBP that_IN
        sub-lethal_JJ radiation_NN is_VBZ effective_JJ in_IN augmenting_VBG adoptive_JJ
        anti-tumor_JJ immunity_NN in_IN the_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD model_NN ,_, underscoring_VBG
        the_DT potential_JJ value_NN of_IN perturbing_VBG the_DT tumor_NN
        microenvironment_NN as_RB well_RB as_IN the_DT lymphoid_NN compartment_NN to_TO
        enhance_VB anti-tumor_JJ immunity_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS carry_VBP the_DT SV_NNP 40_CD early_JJ region_NN under_IN
          control_NN of_IN rat_NN insulin_NN II_NNP promoter_NN [_NN 23_CD ]_NN ._. The_DT
          transgenic_JJ mice_NNS were_VBD maintained_VBN on_IN C_NNP 3_CD HeBFe_NNP background_NN
          with_IN 39_CD -_: 40_CD generations_NNS of_IN backcross_NNS ._. Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS have_VBP
          100_CD %_NN incidence_NN of_IN spontaneous_JJ insulinoma_NN ._. Tag-_NNP TCR_NNP 1_CD
          (_( referred_VBD to_TO hereafter_RB as_IN TCR_NNP )_) transgenic_JJ mice_NNS expressing_VBG
          a_DT T_NN cell_NN receptor_NN transgene_NN with_IN specificity_NN to_TO Tag_NNP were_VBD
          generated_VBN in_IN the_DT B_NNP 6_CD D_NNP 2_CD F_NN 1_CD background_NN and_CC backcrossed_JJ to_TO
          C_NNP 3_CD HeBFe_NNP for_IN 20_CD generations_NNS [_NN 28_CD ]_NN ._. About_IN 10_CD %_NN of_IN the_DT
          splenic_JJ CD_NNP 4_CD +_NN T_NN cells_NNS in_IN this_DT transgenic_JJ line_NN express_VBP the_DT
          TCR_NNP transgene_NN [_NN 28_CD ]_NN ._. All_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD in_IN all_DT treatment_NN
          groups_NNS received_VBD the_DT same_JJ diet_NN throughout_IN the_DT experiment_NN ._.
          All_DT experimental_JJ procedures_NNS were_VBD conducted_VBN in_IN accordance_NN
          with_IN NIH_NNP and_CC University_NNP of_IN California_NNP ,_, San_NNP Francisco_NNP
          guidelines_NNS ._.
        
        
          Intervention_NN and_CC regression_NN trials_NNS
          The_DT Intervention_NN trial_NN was_VBD initiated_VBN when_WRB Rip_NNP 1_CD -_: Tag_NNP 2_CD
          mice_NNS reached_VBD the_DT age_NN of_IN 10_CD weeks_NNS ._. Mice_NNS were_VBD sacrificed_JJ at_IN
          13_CD weeks_NNS of_IN age_NN for_IN the_DT determination_NN of_IN tumor_NN burden_NN ._.
          The_DT Regression_NNP Trial_NNP started_VBD at_IN the_DT age_NN of_IN 12_CD ._. 6_CD weeks_NNS
          (_( about_IN 88_CD days_NNS after_IN birth_NN )_) ._. The_DT end_NN point_NN was_VBD at_IN 16_CD
          weeks_NNS of_IN age_NN ._. In_IN both_DT cases_NNS ,_, cohorts_NNS of_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS
          were_VBD set_VBN up_RP for_IN survival_NN study_NN ._. Mice_NNS were_VBD euthanized_JJ when_WRB
          they_PRP became_VBD moribund_JJ ._.
        
        
          Radiation_NNP of_IN mice_NNS
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS at_IN the_DT specifically_RB defined_VBN age_NN were_VBD
          irradiated_JJ in_IN the_DT Mark_NNP I_PRP model_NN 68_CD A_DT cesium_NN 137_CD irradiator_NN
          (_( J_NNP ._. L_NNP ._. Shepherd_NNP &_CC Associates_NNP ,_, San_NNP Fernando_NNP ,_, CA_NNP )_) ._. The_DT
          dosage_NN used_VBN was_VBD 600_CD R_NN (_( 6_CD Gy_NNP )_) ._.
        
        
          Adoptive_NNP transfer_NN of_IN cells_NNS
          Splenocytes_NNP from_IN TCR_NNP or_CC non-transgenic_JJ C_NNP 3_CD H_NNP mice_NNS were_VBD
          isolated_VBN ._. The_DT cells_NNS were_VBD briefly_NN hemolyzed_JJ ,_, washed_VBD
          extensively_RB in_IN DMEM_NNP containing_VBG 10_CD %_NN FBS_NNP ,_, filtered_VBN through_IN
          a_DT 100_CD μM_NN sterile_JJ nylon_NN filter_NN ,_, counted_VBN by_IN hemacytometer_NN ,_,
          and_CC suspended_VBD in_IN complete_JJ medium_NN ._. The_DT cells_NNS were_VBD adjusted_VBN
          to_TO a_DT density_NN of_IN 1_CD ×_NN 10_CD 8_CD cells_NNS /_NN ml_NN and_CC injected_VBN into_IN the_DT
          intraperitoneal_NN space_NN of_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS ._. Each_DT mouse_NN in_IN
          the_DT treatment_NN received_VBD 1_CD ml_NN of_IN splenocytes_NNS (_( 1_CD ×_NN 10_CD
          8_CD cells_NNS )_) ._. In_IN the_DT group_NN that_WDT received_VBD both_DT radiation_NN and_CC
          splenocyte_NN transfer_NN ,_, mice_NNS were_VBD irradiated_JJ at_IN 600_CD R_NN one_CD day_NN
          prior_RB to_TO splenocyte_NN transfer_NN ._.
        
        
          Calculation_NNP of_IN tumor_NN burden_NN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS in_IN each_DT treatment_NN were_VBD sacrificed_JJ at_IN
          the_DT defined_VBN end_NN points_NNS ._. Solid_NNP tumors_NNS were_VBD isolated_VBN ,_,
          photographed_VBN ,_, and_CC measured_VBD ._. The_DT tumor_NN volume_NN was_VBD
          calculated_VBN using_VBG the_DT following_JJ formula_NN :_: volume_NN =_SYM 0_CD ._. 52_CD ×_NN
          (_( width_NN )_) 2_CD ×_NN (_( length_NN )_) ._. Tumor_NNP burden_NN per_IN mouse_NN was_VBD defined_VBN
          as_IN the_DT sum_NN of_IN the_DT volume_NN of_IN all_DT macroscopic_JJ tumors_NNS ._.
          Intestinal_NNP carcinoid_NN tumors_NNS appear_VBP occasionally_RB in_IN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS ._. Such_JJ tumors_NNS are_VBP associated_VBN with_IN this_DT
          particular_JJ line_NN of_IN Rip-_NNP Tag_NNP transgenic_JJ mice_NNS (_( but_CC not_RB
          others_NNS )_) and_CC were_VBD not_RB the_DT result_NN of_IN any_DT of_IN the_DT treatments_NNS
          in_IN the_DT study_NN ._. Thus_RB ,_, these_DT extra-pancreatic_JJ tumors_NNS were_VBD
          recorded_VBN but_CC not_RB included_VBN in_IN the_DT calculations_NNS in_IN the_DT
          current_JJ study_NN ._.
        
        
          Tissue_NNP preparation_NN and_CC immunohistochemistry_NN
          All_DT histological_JJ analyses_NNS were_VBD done_VBN on_IN frozen_VBN
          sections_NNS ._. Samples_NNP were_VBD fresh_JJ frozen_VBN in_IN Tissue-_NNP Tek_NNP O_NNP ._. C_NNP ._. T_NN ._.
          compound_NN (_( Sakura_NNP Finetek_NNP ,_, Torrance_NNP ,_, CA_NNP USA_NNP )_) and_CC sectioned_JJ
          at_IN 10_CD μM_NN thickness_NN ._. For_IN immunohistochemistry_NN ,_, sections_NNS
          were_VBD briefly_NN fixed_VBN in_IN cold_JJ acetone_NN ._. They_PRP were_VBD then_RB
          blocked_VBN for_IN 1_CD h_NN in_IN PBS_NNP with_IN 5_CD %_NN normal_JJ goat_NN serum_NN ._. Slides_NNS
          were_VBD incubated_JJ at_IN room_NN temperature_NN for_IN 1_CD h_NN with_IN the_DT
          primary_JJ antibodies_NNS ._. The_DT samples_NNS were_VBD washed_VBN extensively_RB
          in_IN PBS_NNP and_CC then_RB incubated_JJ with_IN biotinylated_JJ secondary_JJ
          antibodies_NNS (_( Vector_NNP Laboratories_NNPS ,_, Burlingame_NNP ,_, CA_NNP )_) ._.
          Endogenous_NNP peroxidase_NN activity_NN was_VBD quenched_JJ with_IN 0_CD ._. 6_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD /_NN methanol_NN for_IN 4_CD minutes_NNS ._. Color_NNP on_IN
          sections_NNS was_VBD developed_VBN with_IN ABC-horseradish_NNP peroxidase_NN
          (_( Vector_NNP Laboratories_NNPS )_) and_CC 3_CD ,_, 3_CD '_POS -_: diaminobenzidine_NN substrate_NN
          (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. H_NNP &_CC E_NNP staining_VBG was_VBD performed_VBN
          with_IN hamatoxylin_NN Gill_NNP #_# 3_CD and_CC eosin_NN Y_NNP (_( Sigma_NNP )_) ._.
          The_DT following_VBG antibodies_NNS were_VBD used_VBN for_IN
          immunohistochemistry_NN :_: anti-murine_JJ CD_NNP 4_CD (_( H_NNP 129_CD ._. 9_CD )_) ;_:
          anti-murine_JJ CD_NNP 8_CD (_( 53_CD -_: 6_CD ._. 7_CD )_) ;_: anti-murine_JJ CD_NNP 11_CD c_SYM (_( HL_NNP 3_LS )_) ;_:
          anti-murine_JJ CD_NNP 31_CD (_( MEC_NNP 13_CD ._. 3_LS )_) at_IN recommended_VBD concentrations_NNS
          (_( PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Tumor_NNP burden_NN was_VBD analyzed_VBN using_VBG the_DT Mann-_NNP Whitney_NNP test_NN
          (_( InStat_NNP version_NN 1_CD ._. 12_CD ,_, GraphPad_NNP Software_NNP )_) ._. Survival_NNP data_NNS
          was_VBD analyzed_VBN with_IN a_DT log-rank_JJ test_NN (_( Prizm_NNP 3_CD ._. 0_CD A_DT ,_, GraphPad_NNP
          software_NN )_) ._.
        
      
      
        Results_NNS
        
          Combinatorial_NNP efficacy_NN of_IN adoptive_JJ transfer_NN and_CC
          sub-lethal_JJ radiation_NN
          We_PRP used_VBD two_CD distinctive_JJ therapeutic_JJ trial_NN designs_NNS for_IN
          the_DT treatment_NN of_IN tumors_NNS Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS :_: intervention_NN and_CC
          regression_NN [_NN 33_CD ]_NN ._. In_IN each_DT trial_NN we_PRP used_VBD three_CD
          experimental_JJ arms_NNS as_RB well_RB as_IN an_DT untreated_JJ control_NN group_NN ;_:
          the_DT treatment_NN arms_NNS were_VBD adoptive_JJ transfer_NN of_IN tumor_NN
          antigen_NN specific_JJ T_NN cells_NNS ,_, a_DT sub-lethal_JJ dose_NN of_IN radiation_NN
          (_( 600_CD R_NN )_) ,_, or_CC radiation_NN followed_VBN by_IN adoptive_JJ transfer_NN ._. In_IN
          the_DT intervention_NN trial_NN ,_, treatment_NN occurred_VBD at_IN a_DT time_NN when_WRB
          small_JJ ,_, encapsulated_JJ adenomas_NNS are_VBP forming_VBG (_( week_NN 10_CD for_IN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS )_) ._. The_DT data_NNS are_VBP summarized_VBD in_IN Figure_NN 1_CD ._. The_DT
          mean_JJ tumor_NN volume_NN at_IN the_DT start_NN of_IN the_DT trial_NN was_VBD 3_CD mm_NN 3_CD ._.
          The_DT average_JJ number_NN of_IN tumors_NNS was_VBD 2_CD ._. 4_CD ._. At_IN the_DT end_NN of_IN the_DT
          study_NN ,_, the_DT mean_JJ tumor_NN burden_NN in_IN the_DT untreated_JJ control_NN
          group_NN was_VBD about_IN 34_CD mm_NN 3_CD in_IN volume_NN and_CC 7_CD ._. 6_CD in_IN tumor_NN number_NN ._.
          Adoptive_NNP transfer_NN of_IN splenocytes_NNS from_IN TCR_NNP transgenic_JJ mice_NNS
          into_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS produced_VBD a_DT modest_JJ ,_, but_CC not_RB
          statistically_RB significant_JJ ,_, reduction_NN in_IN tumor_NN volume_NN
          (_( 35_CD %_NN )_) ,_, and_CC no_DT change_NN in_IN tumor_NN number_NN ._. Sub-lethal_NNP
          radiation_NN alone_RB significantly_RB reduced_VBN tumor_NN volume_NN (_( 53_CD %_NN ,_,
          p_NN =_SYM 0_CD ._. 03_CD )_) ,_, but_CC the_DT mice_NNS had_VBD a_DT similar_JJ number_NN of_IN tumors_NNS
          (_( 6_CD ._. 4_LS )_) ._. With_IN the_DT combination_NN treatment_NN ,_, a_DT significant_JJ
          reduction_NN in_IN both_DT tumor_NN volume_NN (_( 87_CD %_NN ;_: p_NN =_SYM 0_CD ._. 0004_CD )_) and_CC
          tumor_NN number_NN was_VBD observed_VBN ._. It_PRP is_VBZ notable_JJ that_IN the_DT mice_NNS
          receiving_VBG the_DT combination_NN treatment_NN had_VBD a_DT mean_JJ tumor_NN
          volume_NN of_IN 4_CD ._. 6_CD mm_NN 3_CD (_( p_NN =_SYM 0_CD ._. 0004_CD )_) and_CC an_DT average_JJ tumor_NN
          number_NN of_IN 2_CD ._. 3_CD ,_, comparable_JJ to_TO the_DT situation_NN at_IN the_DT
          beginning_NN of_IN the_DT trial_NN ._. Thus_RB ,_, a_DT condition_NN of_IN '_POS stable_JJ
          disease_NN '_'' was_VBD achieved_VBN in_IN the_DT group_NN that_WDT received_VBD the_DT
          combinatorial_NN therapy_NN
          In_IN the_DT regression_NN trial_NN ,_, RIP_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS with_IN
          substantial_JJ tumor_NN burden_NN and_CC minimal_JJ life_NN expectancy_NN were_VBD
          treated_VBN beginning_VBG at_IN week_NN 13_CD [_NN 33_CD ]_NN ._. The_DT average_JJ tumor_NN
          volume_NN was_VBD around_IN 22_CD mm_NN 3_CD at_IN the_DT start_NN of_IN the_DT treatment_NN
          (_( Figure_NN 2_LS )_) ._. The_DT tumor_NN burden_NN of_IN the_DT untreated_JJ control_NN
          group_NN at_IN the_DT end_NN of_IN the_DT study_NN was_VBD ~_NN 146_CD mm_NN 3_CD ._. No_DT reduction_NN
          in_IN tumor_NN burden_NN was_VBD observed_VBN following_VBG adoptive_JJ transfer_NN
          of_IN non-transgenic_JJ splenocytes_NNS alone_RB (_( 132_CD %_NN of_IN controls_NNS )_) ._.
          In_IN contrast_NN ,_, sub-lethal_JJ radiation_NN alone_RB resulted_VBD in_IN a_DT
          significant_JJ reduction_NN of_IN tumor_NN burden_NN (_( 63_CD %_NN ,_, p_NN =_SYM 0_CD ._. 01_CD )_) ._.
          The_DT combinatorial_NN treatment_NN produced_VBD an_DT even_RB greater_JJR
          reduction_NN in_IN tumor_NN burden_NN (_( 80_CD %_NN ,_, p_NN =_SYM 0_CD ._. 0009_CD )_) ._. The_DT average_JJ
          tumor_NN number_NN in_IN all_DT groups_NNS was_VBD similar_JJ (_( about_IN 8_CD )_) ._. As_IN
          observed_VBD in_IN the_DT intervention_NN trial_NN ,_, tumor_NN burden_NN in_IN the_DT
          group_NN receiving_VBG the_DT combinatorial_NN treatment_NN had_VBD remained_VBN
          virtually_RB unchanged_JJ ._. Thus_RB ,_, even_RB with_IN substantial_JJ tumor_NN
          burden_NN ,_, the_DT combination_NN of_IN sub-lethal_JJ radiation_NN and_CC
          splenocyte_NN transfer_NN could_MD stop_VB tumor_NN growth_NN during_IN the_DT
          course_NN of_IN the_DT study_NN ._.
        
        
          Sub-lethal_NNP radiation_NN increases_NNS lymphocyte_NN
          infiltration_NN of_IN tumors_NNS
          Because_IN the_DT combination_NN of_IN sub-lethal_JJ radiation_NN and_CC
          TCR_NNP splenocyte_NN transfer_NN lead_VB to_TO significant_JJ reduction_NN in_IN
          tumor_NN burden_NN in_IN both_DT intervention_NN and_CC regression_NN trials_NNS ,_,
          we_PRP asked_VBD whether_IN the_DT radiation_NN had_VBD increased_VBN the_DT number_NN
          of_IN tumor-infiltrating_JJ lymphocytes_NNS ._. Tissue_NNP samples_NNS were_VBD
          collected_VBN three_CD weeks_NNS after_IN treatment_NN in_IN the_DT regression_NN
          trial_NN ._. Immunohistochemistry_NNP was_VBD used_VBN to_TO detect_VB CD_NNP 4_CD +_NN ,_, CD_NNP 8_CD
          +_NN and_CC CD_NNP 11_CD c_SYM +_NN cell_NN infiltration_NN into_IN the_DT tumors_NNS ._. Because_IN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS are_VBP inherently_RB tolerant_NN to_TO Tag_NNP ,_, little_JJ
          infiltration_NN by_IN either_DT T_NN lymphocytes_NNS or_CC dendritic_JJ cells_NNS
          was_VBD observed_VBN in_IN the_DT untreated_JJ control_NN group_NN (_( Figure_NN 3_LS )_) ._.
          In_IN agreement_NN with_IN previous_JJ observations_NNS ,_, little_JJ
          infiltration_NN was_VBD detected_VBN in_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS receiving_VBG TCR_NNP
          splenocyte_NN transfer_NN (_( Figure_NN 3_LS )_) ._. Nor_CC did_VBD radiation_NN alone_RB
          elicit_NN T_NN cell_NN infiltration_NN ,_, although_IN a_DT modest_JJ increase_NN in_IN
          CD_NNP 11_CD c_SYM +_NN dendritic_JJ cell_NN infiltration_NN was_VBD observed_VBN ._. However_RB ,_,
          in_IN both_DT intervention_NN and_CC regression_NN trials_NNS ,_, significant_JJ
          CD_NNP 4_CD +_NN T_NN cell_NN and_CC CD_NNP 8_CD +_NN T_NN cell_NN infiltration_NN into_IN
          hyperplastic_JJ /_NN dysplastic_JJ islets_NNS and_CC tumors_NNS was_VBD noted_VBN in_IN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS that_WDT had_VBD received_VBN the_DT combination_NN of_IN
          sub-lethal_JJ radiation_NN and_CC adoptive_JJ transfer_NN of_IN TCR_NNP
          splenocytes_NNS ._. A_DT modest_JJ increase_NN in_IN CD_NNP 11_CD c_SYM +_NN dendritic_JJ cell_NN
          infiltration_NN was_VBD observed_VBN in_IN the_DT mice_NNS receiving_VBG the_DT
          combination_NN therapy_NN ._. One_PRP should_MD recall_VB that_IN the_DT TCR_NNP mice_NNS
          express_VBP a_DT CD_NNP 4_CD -_: restricted_VBN TCR_NNP ,_, and_CC thus_RB produce_VB increased_VBN
          numbers_NNS of_IN anti-_NN Tag_NNP CD_NNP 4_CD T_NN cells_NNS ,_, and_CC thus_RB we_PRP anticipated_VBD
          a_DT bias_NN in_IN numbers_NNS toward_IN this_DT T_NN cell_NN type_NN ._. Indeed_RB ,_, one_CD
          week_NN after_IN treatment_NN ,_, little_JJ CD_NNP 8_CD +_NN T_NN infiltration_NN of_IN
          premalignant_NN or_CC malignant_JJ lesions_NNS was_VBD detected_VBN in_IN
          Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS receiving_VBG the_DT combinatorial_NN treatment_NN
          (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, three_CD weeks_NNS after_IN
          combinatorial_NN treatment_NN in_IN the_DT regression_NN trial_NN ,_,
          significant_JJ CD_NNP 8_CD +_NN T_NN cell_NN infiltration_NN was_VBD observed_VBN in_IN
          solid_JJ tumors_NNS ,_, suggesting_VBG a_DT broadening_VBG of_IN the_DT T_NN cell_NN
          response_NN from_IN that_DT contained_VBD in_IN the_DT adoptive_JJ
          transfer_NN ._.
        
        
          Combining_NNP adoptive_JJ transfer_NN and_CC sub-lethal_JJ
          radiation_NN prolongs_NNS survival_NN
          The_DT trials_NNS above_IN used_VBN defined_VBN endpoints_NNS (_( 12_CD ._. 6_CD week_NN and_CC
          16_CD week_NN )_) to_TO allow_VB comparison_NN of_IN cumulative_JJ tumor_NN volume_NN
          and_CC number_NN ._. To_TO evaluate_VB the_DT effects_NNS of_IN the_DT various_JJ
          treatments_NNS on_IN survival_NN ,_, we_PRP performed_VBD intervention_NN and_CC
          regression_NN trials_NNS on_IN cohorts_NNS of_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS ,_, in_IN which_WDT
          groups_NNS received_VBD no_DT treatment_NN ,_, radiation_NN alone_RB ,_, or_CC the_DT
          combinatorial_NN treatment_NN ,_, in_IN which_WDT the_DT endpoint_NN was_VBD
          survival_NN ._. Because_IN splenocyte_NN transfer_NN alone_RB had_VBD resulted_VBN
          in_IN no_DT significant_JJ reduction_NN in_IN tumor_NN burden_NN ,_, this_DT group_NN
          was_VBD not_RB tested_VBN for_IN survival_NN benefit_NN ,_, for_IN logistical_JJ
          reasons_NNS ._. All_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS in_IN the_DT study_NN eventually_RB
          succumbed_VBD to_TO their_PRP$ cancers_NNS ._. Although_IN radiation_NN treatment_NN
          alone_RB impaired_VBN tumor_NN growth_NN in_IN both_DT intervention_NN and_CC
          regression_NN trials_NNS ,_, it_PRP produced_VBD no_DT significant_JJ extension_NN
          of_IN survival_NN time_NN in_IN either_DT trial_NN (_( Figure_NN 4_LS )_) ._. In_IN contrast_NN ,_,
          there_EX was_VBD a_DT significant_JJ extension_NN of_IN survival_NN of_IN cohorts_NNS
          receiving_VBG the_DT combinatorial_NN treatment_NN in_IN the_DT intervention_NN
          and_CC regression_NN trials_NNS ._. The_DT effect_NN was_VBD pronounced_VBN in_IN the_DT
          intervention_NN trial_NN ,_, with_IN an_DT extension_NN of_IN survival_NN of_IN 5_CD
          weeks_NNS (_( p_NN <_NN 0_CD ._. 0001_CD ,_, log-rank_JJ )_) ._. In_IN the_DT regression_NN trial_NN
          the_DT extension_NN of_IN survival_NN time_NN was_VBD about_IN 3_CD weeks_NNS (_( p_NN =_SYM
          0_CD ._. 001_CD ,_, log-rank_JJ )_) ._. No_DT extension_NN of_IN survival_NN time_NN was_VBD
          observed_VBN in_IN mice_NNS treated_VBN with_IN 600_CD R_NN and_CC syngeneic_JJ C_NNP 3_CD H_NNP
          splenocytes_NNS (_( p_NN =_SYM 0_CD ._. 6893_CD ,_, log-rank_JJ )_) ._. Thus_RB ,_, the_DT observed_VBN
          reduction_NN of_IN tumor_NN burden_NN produced_VBN by_IN the_DT combinatorial_NN
          treatment_NN translated_VBN into_IN significant_JJ survival_NN advantage_NN ,_,
          and_CC the_DT effect_NN was_VBD dependent_JJ on_IN the_DT increased_VBN frequency_NN
          of_IN tumor-antigen_JJ specific_JJ T_NN cells_NNS from_IN the_DT TCR_NNP
          transgenic_JJ ._.
          Because_IN the_DT single_JJ combination_NN treatment_NN lead_NN to_TO clear_VB
          therapeutic_JJ benefits_NNS and_CC yet_RB did_VBD not_RB eradicate_VB
          established_VBN tumors_NNS ,_, we_PRP asked_VBD whether_IN mice_NNS would_MD benefit_VB
          from_IN repeated_VBN treatments_NNS ._. Both_DT intervention_NN and_CC
          regression_NN trials_NNS were_VBD conducted_VBN ._. Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS were_VBD
          given_VBN the_DT combination_NN treatment_NN at_IN 10_CD -_: weeks_NNS and_CC again_RB at_IN
          13_CD -_: weeks_NNS of_IN age_NN for_IN an_DT intervention_NN trial_NN ,_, or_CC at_IN 13_CD and_CC
          16_CD -_: weeks_NNS for_IN a_DT regression_NN trial_NN ._. Survival_NNP was_VBD monitored_VBN
          over_IN time_NN ._. The_DT results_NNS show_VBP no_DT added_VBN survival_NN benefit_NN
          when_WRB the_DT treatment_NN regimen_NN was_VBD repeated_VBN (_( Figure_NN 4_LS )_) ._. The_DT
          mean_JJ survival_NN time_NN was_VBD statistically_RB equivalent_JJ to_TO that_DT
          observed_VBD in_IN the_DT groups_NNS given_VBN a_DT single_JJ combinatorial_NN
          treatment_NN in_IN the_DT intervention_NN trial_NN ,_, and_CC in_IN the_DT
          regression_NN trial_NN the_DT cohort_NN given_VBN a_DT double_JJ combinatorial_NN
          treatment_NN showed_VBD no_DT significant_JJ extension_NN of_IN survival_NN
          time_NN as_IN compared_VBN to_TO untreated_JJ controls_NNS (_( p_NN =_SYM 0_CD ._. 07_CD ,_,
          log-rank_JJ )_) ._.
        
      
      
        Discussion_NNP
        Previous_JJ studies_NNS using_VBG lethal_JJ dose_NN radiation_NN and_CC bone_NN
        marrow_NN transplant_NN prior_RB to_TO CD_NNP 4_CD +_NN T_NN cell_NN transfer_NN in_IN another_DT
        Rip-_NNP Tag_NNP line_NN of_IN mice_NNS indicated_VBD that_IN such_JJ treatment_NN could_MD
        produce_VB a_DT modest_JJ increase_NN in_IN the_DT number_NN of_IN
        tumor-infiltrating_JJ T_NN cells_NNS [_NN 22_CD ]_NN ._. The_DT current_JJ study_NN
        extends_VBZ the_DT thesis_NN by_IN focusing_VBG on_IN the_DT use_NN of_IN sub-lethal_JJ
        radiation_NN to_TO enhance_VB the_DT anti-tumor_JJ immunity_NN of_IN adoptively_RB
        transferred_VBN tumor-antigen-specific_JJ lymphocytes_NNS in_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD
        mice_NNS ._. The_DT splenocytes_NNS were_VBD derived_VBN from_IN T_NN cell_NN receptor_NN
        transgenic_JJ mice_NNS that_WDT preferentially_RB enhanced_JJ development_NN of_IN
        CD_NNP 4_CD +_NN T_NN cells_NNS recognizing_VBG a_DT peptide_NN within_IN the_DT SV_NNP 40_CD large_JJ T_NN
        oncoprotein_NN [_NN 28_CD ]_NN ._. While_IN the_DT transfer_NN of_IN naive_JJ
        splenocytes_NNS from_IN the_DT TCR_NNP transgenic_JJ mice_NNS had_VBD no_DT effect_NN on_IN
        tumor_NN development_NN ,_, sub-lethal_JJ radiation_NN prior_RB to_TO lymphocyte_NN
        transfer_NN resulted_VBN in_IN significant_JJ reduction_NN in_IN tumor_NN burden_NN
        in_IN both_DT intervention_NN and_CC regression_NN trials_NNS ._. In_IN addition_NN ,_,
        Rip_NNP 1_CD -_: Tag_NNP 2_CD mice_NNS receiving_VBG the_DT combinatorial_NN treatment_NN had_VBD
        significantly_RB longer_JJR survival_NN time_NN than_IN those_DT receiving_VBG
        single_JJ treatment_NN ._.
        Immunohistochemical_NNP analysis_NN indicates_VBZ that_IN the_DT
        combinatorial_NN treatment_NN dramatically_RB increased_VBD the_DT level_NN of_IN
        infiltration_NN by_IN CD_NNP 4_CD +_NN lymphocytes_NNS and_CC CD_NNP 11_CD c_SYM +_NN dendritic_JJ cells_NNS
        into_IN solid_JJ tumors_NNS ._. Due_JJ to_TO the_DT nature_NN of_IN this_DT line_NN of_IN TCR_NNP
        transgenic_JJ mice_NNS ,_, only_RB about_IN 10_CD %_NN of_IN splenic_JJ CD_NNP 4_CD +_NN T_NN cells_NNS are_VBP
        Tag-specific_NNP ._. Thus_RB ,_, it_PRP is_VBZ possible_JJ that_IN some_DT of_IN the_DT
        tumor-infiltrating_JJ ,_, CD_NNP 4_CD +_NN T_NN cells_NNS may_MD recognize_VB targets_NNS
        other_JJ than_IN Tag_NNP ._. This_DT may_MD be_VB the_DT result_NN of_IN the_DT "_'' bystander_NN "_''
        effects_NNS induced_VBN by_IN the_DT tumor-infiltrating_JJ ,_, Tag-specific_NNP ,_,
        CD_NNP 4_CD +_NN T_NN cells_NNS ._. The_DT elucidation_NN of_IN this_DT phenomenon_NN with_IN
        idiotype-specific_JJ antibodies_NNS or_CC tetramers_NNS in_IN future_JJ
        experiments_NNS would_MD clarify_VB the_DT extent_NN of_IN "_'' bystander_NN "_'' effects_NNS
        in_IN this_DT model_NN ._. Although_IN delayed_VBN when_WRB compared_VBN to_TO CD_NNP 4_CD +_NN T_NN
        cell_NN infiltration_NN ,_, CD_NNP 8_CD +_NN T_NN cell_NN infiltration_NN became_VBD more_RBR
        extensive_JJ over_IN time_NN ._. We_PRP speculate_VBP that_IN the_DT
        tumor-infiltrating_JJ ,_, CD_NNP 4_CD +_NN T_NN cells_NNS would_MD induce_VB the_DT
        activation_NN and_CC tumor-infiltration_JJ of_IN CD_NNP 8_CD +_NN T_NN cells_NNS present_JJ
        in_IN the_DT transferred_VBN transgenic_JJ splenocytes_NNS ._. This_DT pattern_NN ,_, as_RB
        well_RB as_IN the_DT origin_NN of_IN the_DT splenocytes_NNS ,_, suggests_VBZ that_IN CD_NNP 4_CD +_NN T_NN
        cells_NNS can_MD play_VB a_DT predominant_NN and_CC effective_JJ role_NN in_IN
        controlling_VBG tumor_NN growth_NN ._.
        Previous_JJ studies_NNS have_VBP indicated_VBN that_IN solid_JJ tumors_NNS can_MD be_VB
        resistant_JJ to_TO the_DT infiltration_NN of_IN tumor-specific_JJ T_NN cells_NNS ._.
        The_DT data_NNS presented_VBN here_RB suggest_VBP that_IN such_JJ resistance_NN can_MD be_VB
        disrupted_VBN by_IN sub-lethal_JJ radiation_NN ._. Several_JJ possible_JJ
        mechanisms_NNS for_IN the_DT enhancing_VBG effects_NNS of_IN sub-lethal_JJ
        radiation_NN on_IN anti-tumor_JJ immunity_NN can_MD be_VB envisioned_VBN ,_, as_IN
        discussed_VBN below_IN ._. First_LS ,_, sub-lethal_JJ radiation_NN may_MD reduce_VB
        antigen-specific_JJ immune_JJ tolerance_NN mediated_JJ by_IN bone_NN
        marrow-derived_JJ cells_NNS ,_, including_VBG regulatory_JJ T_NN cells_NNS ,_, in_IN the_DT
        tumor-draining_JJ lymph_NN nodes_NNS ._. Previous_JJ studies_NNS have_VBP shown_VBN
        that_IN adoptively_RB transferred_VBN tumor_NN antigen-specific_JJ CD_NNP 4_CD +_NN T_NN
        cells_NNS can_MD be_VB tolerized_JJ in_IN the_DT secondary_JJ lymphoid_NN organs_NNS [_NN 9_CD
        34_CD ]_NN ,_, including_VBG the_DT RIP-Tag_NNP 2_CD model_NN [_NN 30_CD ]_NN ._. Radiation_NNP may_MD
        kill_VB or_CC disable_JJ regulatory_JJ T_NN cells_NNS [_NN 35_CD 36_CD ]_NN ,_, or_CC other_JJ
        bone_NN marrow-derived_JJ tolerizing_VBG cells_NNS and_CC prevent_VB the_DT
        induction_NN of_IN tolerance_NN in_IN adoptively_RB transferred_VBN
        tumor-specific_JJ T_NN cells_NNS [_NN 9_CD ]_NN ._. Additionally_RB ,_, the_DT high_JJ but_CC
        sub-lethal_JJ dose_NN of_IN radiation_NN used_VBN leads_VBZ to_TO significant_JJ
        lymphopenia_NN [_NN 37_CD ]_NN ._. The_DT sudden_JJ reduction_NN in_IN lymphocyte_NN
        number_NN may_MD create_VB the_DT spatial_NN allowance_NN in_IN spleen_NN and_CC lymph_NN
        nodes_NNS necessary_JJ for_IN the_DT homing_VBG ,_, activation_NN and_CC expansion_NN of_IN
        he_PRP adoptively-transferred_JJ T_NN cells_NNS ._. The_DT increase_NN of_IN
        tumor-specific_JJ CD_NNP 4_CD +_NN T_NN cells_NNS in_IN the_DT tumor-draining_JJ lymph_NN
        nodes_NNS could_MD then_RB enhance_VB the_DT infiltration_NN of_IN T_NN cells_NNS inside_IN
        the_DT solid_JJ tumors_NNS ._.
        Second_JJ ,_, radiation-induced_JJ damage_NN or_CC abnormality_NN may_MD
        induce_VB a_DT "_'' tissue_NN damage_NN signal_NN "_'' in_IN the_DT solid_JJ tumors_NNS through_IN
        radiation-mediated_JJ apoptosis_NNS [_NN 38_CD ]_NN ._. There_EX is_VBZ mounting_VBG
        evidence_NN that_IN apoptotic_JJ cell_NN death_NN is_VBZ not_RB immunologically_RB
        benign_JJ ,_, but_CC can_MD trigger_VB immune_JJ responses_NNS [_NN 39_CD 40_CD ]_NN ._. For_IN
        example_NN ,_, cells_NNS treated_VBN with_IN ultraviolet_NN radiation_NN can_MD
        provide_VB potent_JJ adjuvant_NN function_NN in_IN vivo_NN [_NN 41_CD ]_NN ._.
        Sub-lethal_NNP radiation_NN could_MD result_VB in_IN altered_VBN expression_NN of_IN
        pro_FW or_CC anti-inflammatory_JJ chemokines_NNS [_NN 42_CD 43_CD 44_CD ]_NN or_CC
        increased_VBN expression_NN of_IN T_NN cell_NN co-stimlulatory_JJ molecules_NNS
        (_( i_NNP ._. e_SYM ._. B_NNP 7_CD -_: 1_LS )_) on_IN tumor_NN cells_NNS [_NN 45_CD ]_NN ._. Radiation_NNP has_VBZ been_VBN
        shown_VBN to_TO increase_VB the_DT expression_NN of_IN MHC_NNP class_NN I_PRP and_CC II_NNP
        molecules_NNS in_IN tumor_NN cell_NN lines_NNS [_NN 46_CD 47_CD ]_NN ._. Thus_RB ,_, the_DT tissue_NN
        damage_NN signals_NNS evoked_JJ by_IN ionizing_VBG radiation_NN may_MD trigger_VB the_DT
        activation_NN and_CC infiltration_NN of_IN antigen-presenting_JJ cells_NNS ,_, in_IN
        particular_JJ dendritic_JJ cells_NNS [_NN 38_CD 48_CD 49_CD 50_CD ]_NN ._. Indeed_RB ,_, in_IN the_DT
        regression_NN study_NN ,_, we_PRP observe_VBP some_DT increase_NN of_IN
        tumor-infiltrating_JJ dendritic_JJ cells_NNS in_IN the_DT group_NN receiving_VBG
        the_DT single_JJ radiation_NN treatment_NN ._. It_PRP is_VBZ possible_JJ that_IN
        radiation-induced_JJ ,_, tumor-infiltrating_JJ dendritic_JJ cells_NNS may_MD
        facilitate_VB sustained_VBN activation_NN and_CC infiltration_NN of_IN the_DT
        adoptively_RB transferred_VBN CD_NNP 4_CD +_NN T_NN cells_NNS in_IN solid_JJ tumors_NNS in_IN the_DT
        combination_NN group_NN ._.
        Third_NNP ,_, radiation_NN may_MD alter_VB the_DT biophysical_JJ structures_NNS of_IN
        tumors_NNS ,_, which_WDT in_IN some_DT tumors_NNS has_VBZ the_DT capability_NN to_TO impair_VB
        the_DT infiltration_NN or_CC function_NN of_IN tumor-specific_JJ T_NN cells_NNS ._. For_IN
        example_NN ,_, in_IN the_DT related_VBN Rip_NNP 1_CD -_: Tag_NNP 5_CD model_NN ,_, the_DT vascular_NN
        addressins_NNS GlyCAM-_NNP 1_CD and_CC MAdCAM-_NNP 1_CD are_VBP expressed_VBN in_IN
        pre-malignant_JJ islets_NNS ,_, but_CC down-regulated_JJ in_IN solid_JJ tumors_NNS ;_:
        their_PRP$ downregulation_NN coincides_VBZ with_IN lack_NN of_IN infiltration_NN in_IN
        this_DT model_NN of_IN spontaneous_JJ anti-tumor_JJ immunity_NN [_NN 19_CD ]_NN ._. It_PRP
        is_VBZ possible_JJ that_IN sub-lethal_JJ radiation_NN is_VBZ altering_VBG the_DT
        expression_NN of_IN endothelial_NN adhesion_NN molecules_NNS allowing_VBG
        binding_JJ and_CC extravasation_NN of_IN activated_VBN tumor-specific_JJ
        lymphocytes_NNS ._. Another_DT study_NN suggested_VBD that_DT liver_NN endothelial_NN
        cells_NNS can_MD induce_VB antigen-specific_JJ tolerance_NN of_IN CD_NNP 8_CD +_NN T_NN cells_NNS
        [_NN 51_CD ]_NN ._. Perhaps_RB RIP-Tag_NNP tumor_NN endothelium_NN develops_VBZ a_DT
        similar_JJ capability_NN to_TO induce_VB tolerance_NN to_TO extravasating_VBG CD_NNP 4_CD
        +_NN T_NN cells_NNS ,_, a_DT capability_NN disrupted_VBN by_IN radiation_NN ._.
        Finally_RB ,_, it_PRP is_VBZ worth_JJ noting_VBG that_IN the_DT tumors_NNS in_IN Rip_NNP 1_CD -_: Tag_NNP 2_CD
        mice_NNS are_VBP not_RB only_RB highly_RB vascularized_JJ ,_, but_CC also_RB visibly_RB and_CC
        histologically_RB hemorraghic_JJ ._. The_DT hemorraghic_JJ phenotype_NN
        persisted_VBD in_IN all_DT single_JJ agent_NN trials_NNS ,_, but_CC the_DT combination_NN
        trial_NN was_VBD distinct_JJ ._. The_DT mice_NNS in_IN the_DT combination_NN treatment_NN
        group_NN typically_RB had_VBD "_'' white_JJ "_'' tumors_NNS that_WDT lacked_VBD visible_JJ
        microhemorrhaging_VBG ._. A_DT recent_JJ study_NN has_VBZ suggested_VBN that_IN
        tumor-specific_JJ ,_, CD_NNP 4_CD +_NN T_NN cells_NNS can_MD exert_VB anti-tumor_JJ effects_NNS
        by_IN inhibiting_VBG angiogenesis_NNS via_IN release_NN of_IN IFN-γ_NNP [_NN 11_CD ]_NN ._.
        Thus_RB ,_, the_DT "_'' white_JJ "_'' tumors_NNS noted_VBD in_IN the_DT current_JJ study_NN may_MD be_VB
        indicative_JJ of_IN angiogenic_JJ inhibition_NN by_IN the_DT infiltrating_VBG
        tumor-specific_JJ ,_, CD_NNP 4_CD +_NN T_NN cells_NNS ,_, and_CC such_JJ inhibition_NN may_MD be_VB
        relevant_JJ to_TO the_DT observed_VBN efficacy_NN ._. An_DT analysis_NN of_IN the_DT tumor_NN
        vasculature_NN in_IN the_DT combination_NN trial_NN by_IN immunohistochemical_JJ
        staining_VBG for_IN the_DT endothelial_NN cell_NN marker_NN CD_NNP 31_CD revealed_VBD no_DT
        obvious_JJ structural_JJ or_CC density_NN changes_NNS in_IN tumor_NN blood_NN
        vessels_NNS (_( data_NNS not_RB shown_VBN )_) ._. Future_JJ analysis_NN of_IN molecular_JJ
        markers_NNS of_IN the_DT tumor_NN vasculature_NN during_IN and_CC after_IN the_DT
        combinatorial_NN treatment_NN will_MD explore_VB the_DT possibility_NN that_IN
        more_JJR subtle_JJ vascular_NN changes_NNS are_VBP responsible_JJ for_IN the_DT
        observed_VBN efficacy_NN ._.
        While_IN the_DT underlying_VBG mechanisms_NNS remain_VBP unknown_JJ ,_, it_PRP is_VBZ
        evident_JJ that_IN a_DT combination_NN of_IN sub-lethal_JJ radiation_NN and_CC the_DT
        transfer_NN of_IN tumor-specific_JJ CD_NNP 4_CD +_NN lymphocytes_NNS can_MD have_VB a_DT
        synergistic_JJ effect_NN on_IN tumor_NN regression_NN ._. While_IN the_DT
        anti-tumor_JJ effect_NN of_IN the_DT combinatorial_NN treatment_NN does_VBZ not_RB
        completely_RB resolve_VB tumor_NN burden_NN and_CC the_DT mice_NNS eventually_RB
        succumb_NN ,_, it_PRP is_VBZ important_JJ to_TO recognize_VB that_IN the_DT Rip_NNP 1_CD -_: Tag_NNP 2_CD
        mice_NNS are_VBP a_DT very_RB stringent_JJ system_NN for_IN assaying_VBG
        immunotherapies_NNS because_IN of_IN the_DT multifocal_NN nature_NN of_IN tumor_NN
        progression_NN in_IN these_DT mice_NNS ._. Because_IN the_DT Tag_NNP oncogene_NN is_VBZ
        expressed_VBN in_IN all_DT of_IN the_DT ~_NN 500_CD ,_, 000_CD pancreatic_JJ β_NN cells_NNS ,_, each_DT
        of_IN ~_NN 400_CD islets_NNS can_MD be_VB considered_VBN an_DT independent_JJ
        pre-malignant_JJ focus_NN ._. Hence_RB ,_, the_DT immunotherapy_NN tested_VBD herein_NN
        would_MD have_VB to_TO destroy_VB all_DT neoplastic_JJ foci_NN to_TO affect_VB a_DT
        complete_JJ cure_NN ,_, which_WDT is_VBZ perhaps_RB too_RB much_JJ to_TO expect_VB ;_: our_PRP$
        view_NN is_VBZ that_IN the_DT stringency_NN of_IN this_DT system_NN has_VBZ advantages_NNS
        as_IN a_DT readout_NN for_IN therapeutic_JJ strategies_NNS ,_, in_IN the_DT observed_VBN
        efficacy_NN may_MD be_VB more_RBR predictive_JJ of_IN responses_NNS in_IN the_DT clinic_NN
        that_IN those_DT observed_VBN with_IN subcutaneous_JJ tumors_NNS ._. We_PRP expect_VBP
        that_DT clarification_NN of_IN the_DT underlying_VBG mechanism_NN may_MD provide_VB
        avenues_NNS to_TO improved_VBN therapeutic_JJ strategies_NNS based_VBN on_IN the_DT
        concept_NN of_IN disrupting_VBG the_DT evident_JJ barriers_NNS to_TO effective_JJ
        anti-tumor_JJ immunity_NN erected_VBN by_IN solid_JJ tumors_NNS ._. We_PRP suggest_VBP
        that_IN the_DT combinatorial_NN approach_NN presented_VBN here_RB merits_NNS
        consideration_NN in_IN the_DT design_NN of_IN clinical_JJ trials_NNS aimed_VBN to_TO
        achieve_VB T_NN cell-mediated_JJ anti-tumor_JJ immunity_NN ._.
      
      
        Competing_VBG interests_NNS
        none_NN declared_VBD
      
      
        Abbreviations_NNP
        TCR_NNP ,_, T_NN cell_NN receptor_NN ;_: MHC_NNP ,_, major_JJ histocompatibility_NN
        complex_JJ ;_: H-_NNP 2_CD ,_, murine_NN MHC_NNP locus_JJ ;_: Tag_NNP ,_, SV_NNP 40_CD T_NN antigen_NN ;_: RIP_NNP ,_,
        rat_NN insulin_NN promoter_NN ;_: RAG_NNP ,_, recombinase_NN activating_VBG gene_NN ._.
      
    
  
